Protein clearance is critical for the maintenance of the integrity of neuronal cells, and there is accumulating evidence that in most—if not all—neurodegenerative disorders, impaired protein clearance fundamentally contributes to functional and structural alterations eventually leading to clinical symptoms. Dysfunction of protein clearance leads to intra- and extraneuronal accumulation of misfolded proteins and aggregates. The pathological hallmark of Lewy body disorders (LBDs) is the abnormal accumulation of misfolded proteins such as alpha-synuclein (Asyn) and amyloid-beta (Abeta) in a specific subset of neurons, which in turn has been related to deficits in protein clearance. In this paper we will highlight common intraneuronal (including autophagy and unfolded protein stress response) and extraneuronal (including interaction of neurons with astrocytes and microglia, phagocytic clearance, autoimmunity, cerebrospinal fluid transport, and transport across the blood-brain barrier) protein clearance mechanisms, which may be altered across the spectrum of LBDs. A better understanding of the pathways underlying protein clearance—in particular of Asyn and Abeta—in LBDs may result in the identification of novel biomarkers for disease onset and progression and of new therapeutic targets.
1. Introduction
Lewy body disorders (LBDs) is an umbrella term that includes diseases with alpha-synuclein (Asyn) aggregates as fibrils in Lewy bodies (LBs) and Lewy neurites. Several lines of evidence support a pathogenic role of misfolded Asyn in LBDs [1–3]. Parkinson’s disease (PD) without dementia (PDND) is the most common subtype of LBDs, followed by PD with dementia (PDD) and dementia with Lewy bodies (DLBs) [4, 5]. Like in PD, the core feature of PDD is a diagnosis of PD according to the UK Brain Bank Society criteria [6] but also includes cognitive symptoms severe enough to fulfil dementia criteria at least one year after PD diagnosis with insidious onset, slow progression, and impairment in more than one cognitive domain [7]. DLB is the second most prevalent neurodegenerative dementia after Alzheimer’s disease (AD). Clinical diagnosis is based on the presence of a dementia syndrome, accompanied by at least two out of the three following symptoms: fluctuating cognition with pronounced variations in attention and alertness, visual hallucinations, and Parkinsonism [8]. In contrast to PDD, the onset of dementia in DLB is before or within one year of any Parkinsonism.
About one-fourth of LBDs patients show cortical amyloid-beta (Abeta) deposition, with the highest proportion in DLB subjects, followed by PDD subjects [9–14]. According to clinical, neuroimaging, and neuropathological data, co-occurrence of Asyn and Abeta is regularly associated with dementia in LBDs [13–15].
Based on the central role that Asyn and Abeta play in the pathogenesis of LBDs and the increasing body of literature pointing to defective clearance of misfolded proteins as a key mechanism to the pathogenesis of LBDs, this paper aims at providing a condensed review of this latter topic. Although not exhaustive, it may provide a basic understanding of such mechanisms eventually contributing to the development of novel disease biomarkers (which are currently not available [16, 17]) and neuromodulatory treatment strategies for these still incurable and chronic diseases.
2. General Mechanisms of Protein Clearance
The main (intraneuronal) pathways for the degradation and recycling of proteins are the ubiquitin/proteasome system (UPS) and the autophagy-lysosomal pathway (macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA)).
The UPS degrades short-lived nuclear and cytosolic proteins or misfolded proteins in the endoplasmic reticulum [18]. It plays a key role in signal transduction, cell cycle progression, apoptosis, and cellular differentiation and has been implicated in several human diseases, including neurodegenerative diseases, cancer, inflammation, and autoimmunity [18–20].
Autophagy is a process involving the degradation of components inside lysosomes [21, 22]. It has a variety of physiological and pathophysiological roles in protein and organelle clearance, development, defence against microorganisms, cell death, and antigen presentation [23]. In macroautophagy, organelles and macromolecular components are first surrounded by a double membrane, defined as the autophagosome or autophagic vacuole (AV), which then fuses with lysosomes to form autolysosomes. In microautophagy, the transfer of cytosolic components the lysosomal compartment happens by direct invagination of the lysosomal membrane without prior sequestration into the autophagosome. Finally, in CMA, individual proteins are targeted to lysosomes by the binding of a hsc70-containing chaperone/cochaperone complex.
All these pathways are observable in neurons, and both impairment and excessive activation of these pathways are linked to neurodegenerative processes [24].
(Extraneuronal) clearance pathways include interaction of neurons with astro- and microglia and with infiltrating macrophages. Microglial cells are considered the professional phagocytes in the brain. However, other populations of cells may also act as phagocytes, including astrocytes, neural stem cells, and neurons [25–28]. There is no clear evidence for a defective protein clearance by the brain innate immune system as a primary pathogenetic event in neurodegenerative diseases. However, phagocytosis of misfolded proteins by astro- and microglia triggers the release of proinflammatory cytokines and chemokines and reactive oxygen/nitrogen species, which may, under pathological conditions, further promote neuronal dysfunction and degeneration [29, 30].
The adaptive immune system is also involved in the clearance of misfolded proteins in the brain. Naturally occurring autoantibodies are detectable in body fluids of healthy controls and in patients with neurodegenerative disorders [31–33]. Finally, protein transport from the parenchyma to the cerebrospinal fluid (CSF) and across the blood-brain barrier are relevant clearance mechanisms and have been shown to be affected in LBDs.
Intra- and extraneuronal clearance mechanisms closely interact: as an example, protein aggregates can stimulate the cell surface innate immune receptors, initiating intracellular signaling cascades that, in turn, stimulate phagocytosis. An overview of how these mechanisms may interact is schematically illustrated in Figure 1.
Intra- and extraneuronal mechanisms of protein clearance. The main intracellular pathways for the degradation and recycling of proteins are the ubiquitin/proteasome system (UPS) and the autophagy-lysosomal pathway (microautophagy, macroautophagy, and chaperone-mediated autophagy (CMA)). Extracellular clearance pathways include interaction of neurons with astro- and microglia, and with infiltrating macrophages, autoantibodies, and protein transport from the parenchyma to the cerebrospinal fluid and across the blood-brain barrier. The engulfment of misfolded proteins by astro- and microglia triggers the release of proinflammatory cytokines and chemokines as well as reactive oxygen/nitrogen species, which may, under pathological conditions, further promote neuronal dysfunction and degeneration.
In the following, all these mechanisms are discussed in more detail with special emphasis on Asyn and Abeta clearance.
3. Asyn Clearance 3.1. Intraneuronal Mechanisms
Abnormal deposition of Asyn occurs early in the disease process of LBDs and may follow an ascending pattern in most of the cases, starting from lower brainstem areas and then affecting limbic and cortical areas [34]. Deposition may start even earlier in the autonomic peripheral nervous system [35, 36]. The mechanisms responsible for Asyn degradation have been controversial, but it appears that, under normal conditions, Asyn is degraded by both the UPS and the autophagy-lysosomal pathway [37–39], whereas the autophagy-lysosomal pathway mediates clearance of accumulated and aggregated Asyn [38]. In agreement with this observation, activation of autophagy leads to increased wild-type Asyn clearance and neuroprotection [37, 40]. Normal Asyn binds to the CMA-specific receptor LAMP-2A on the lysosomal membrane and is subsequently degraded by CMA. However, mutant forms of Asyn (A53T and A30P) and Asyn modified by dopamine tightly bind to the CMA receptors on the lysosomal membrane and inhibit both their own degradation and that of other CMA substrates [38, 41]. The dysfunction of CMA triggers neuronal dysfunction and increases vulnerability to stress. Interestingly, both mutant and wild-type Asyn can decrease proteasomal activity and increase vulnerability to neurodegeneration, leading to a vicious cycle where an increased amount of intraneuronal Asyn can block its clearance by itself [38, 42–46].
Several studies provide evidence for impaired autophagy-mediated clearance mechanisms in PD. The main proteins involved in CMA (Lamp2a and Hsc70) are decreased in the SN and amygdala from PD patients [46]. Microtubule-associated protein 1A/1B-light chain 3 (LC3, a marker for autophagic vacuoles) colocalizes with Asyn in most LBs and Lewy neurites [46].
Genetic mutations leading to Parkinsonism support the hypothesis that defective clearance mechanisms are centrally involved also in idiopathic forms of LBDs. Interaction between PINK1 and Parkin can modulate mitophagy [47, 48]. PINK1 itself directly activates autophagy and interacts with autophagic proteins such as Beclin1 [49]. A reduced clearance of mitochondria was also demonstrated in cells lacking DJ-1 which is another protein associated with recessive forms of Parkinsonism [50]. Mutations in the LRRK2 gene, the most common form of late onset autosomal dominant Parkinsonism, may also cause neuronal cell death via impairment of protein degradation pathways as they influence the autophagy-lysosomal pathway, leading to Asyn accumulation and aggregation [51, 52]. Heterozygous mutations in the gene encoding the lysosomal enzyme glucocerebrosidase (GBA) convey an approximately 5-fold risk for PD. These mutations are associated with lysosomal dysfunction and influence binding of Asyn to its specific receptor at the lysosome membrane: a recent study demonstrated that the accumulation of the GBA substrate glucosylceramide stabilizes Asyn soluble oligomers which, in turn, can inhibit normal GBA lysosomal activity. This creates a positive feedback loop that could directly contribute to the neurodegenerative process [53]. The heterozygous GBA mutation also seems to directly influence fatty acid metabolism: PD patients with these mutations have lower CSF levels of palmitoleic, oleic, linoleic, arachidonic, eicosapentaenoic, and docosahexaenoic acids compared with both idiopathic PD patients and controls [54].
3.2. Extraneuronal Mechanisms (Mainly)
Although Asyn is a cytosolic protein, a low quantity of the protein is secreted via vesicle exocytosis and is then present in biological fluids including plasma and CSF [55–57]. The mechanisms responsible for the extraneuronal clearance of Asyn are not entirely clear; however, there is increasing evidence that adjacent cells such as astrocytes and microglia as well as the adaptive immune system and local protein transport mechanisms are crucially involved.
Loss of midbrain dopaminergic neurons and striatal degeneration can be preceded by neuroinflammation marked by activated microglia and an increase in proinflammatory cytokines and chemokines [29, 30, 58–62]. Astrocytes are also involved in the initiation and progression of the disease [63]. A recent study showed that astrocytic Asyn initiates noncell autonomous killing of neurons [64]. Indeed, extraneuronal forms of Asyn can activate glial cells and trigger inflammation and subsequent release of proinflammatory molecules, a common pathological hallmark of LBDs [60, 65]. Several studies have reported Asyn-containing inclusions in astroglia of PD and DLB patients [66], and phagocytic microglial cells are very efficient scavengers of extraneuronal Asyn aggregates [63, 67].
Results of recent GWAS studies argue for the relevance of the immune system, in the pathophysiology of LBDs, as variations in the human leukocyte antigen (HLA) region were associated with occurrence of LBDs [68, 69]. This may also be mediated through microglia as these cells are capable of presenting antigens to lymphocytes [70] via the HLA domain. Activation of HLA-positive microglia is observable in affected brain regions of PD patients [71]. Asyn autoantibodies are more prevalent in sera of PD patients than in controls [31]. These results were basically confirmed by a recent study where serum Asyn autoantibody levels were higher in demented LBDs patients than in controls [72].
An overload of local Asyn can also occur due to defective transport mechanisms of Asyn from the neuron to the CSF. Most studies investigating CSF total Asyn levels in PD showed that these levels are reduced in the CSF of PD patients compared to controls, whereas oligomeric Asyn levels seem to be higher in PD compared to control CSF [57, 73–77]. A recent study showed that CSF levels of phosphorylated Asyn correlate weakly with PD severity and, if corrected for total Asyn, contributed to the differential diagnosis between PD, multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) [78]. However, it is neither clear to date how Asyn is transported from the parenchyma to the CSF, nor why total Asyn is reduced and pathological forms of Asyn are elevated in the CSF of PD patients.
4. Abeta Clearance: Lessons from Alzheimer’s Disease Research
Comparable to LBDs pathophysiology, in AD, only some rare genetic mutations lead to increased APP expression or to changes in Abeta stability or aggregation [79]. The common late onset sporadic AD seems to be far better explained by impaired Abeta clearance mechanisms [80]. Thus, assuming that similar mechanisms may occur in (late onset) AD and LBDs and that Abeta pathology is a pathophysiologically relevant feature of LBDs, a discussion of (ineffective) Abeta clearance mechanisms as they occur in AD may substantially contribute to our understanding of how Abeta may (or may not) be cleared in LBDs.
4.1. Intraneuronal Mechanisms
There is convincing evidence from electron microscopy studies [81] that the autophagy-lysosomal pathway is involved in the pathogenesis of AD. AVs which are the major reservoir of intraneuronal Abeta are abundant in affected neurons, especially in those with neurofibrillary tangles [82]. These studies argue for an impaired maturation of autophagolysosomes and impaired intraneuronal retrograde transport in AD. Defective clearance of Abeta-generating AVs may result in Abeta accumulation [83, 84]. Several further findings corroborate the hypothesis that impaired autophagy plays a key role in the pathogenesis of neuronal degeneration in AD. Beclin1 is decreased in AD brains, and decreased neuronal autophagy and subsequent lysosomal dysfunction and neurodegeneration are observed in mice carrying a heterozygous deletion of Beclin1 [85]. Presenilin 1 (PS1) is essential for maturation of the lysosomal proton pump and affects autophagocytosis and protein turnover [86].
4.2. Extraneuronal Clearance Mechanisms (Mainly)
Abeta concentration is tightly regulated by amyloid-degrading proteolytic enzymes and perivascular drainage [87–89]. Neprilysin (NEP) is an Abeta-degrading protein found at presynaptic terminals and in body fluids [90, 91]. It is a preferentially membrane-bound, presynaptically located protein with an extracellular catalytic site which can degrade Abeta [90, 91]. A soluble form of NEP is detectable in body fluids such as blood and CSF, emanating from a slow release from the membranes [92]. Most interestingly, reduced CSF NEP activity levels have been shown to occur in early AD [93, 94].
Another protein involved in defective clearance mechanisms in AD is cystatin C. Neurons, among other cells, are able to produce and secrete this protein [95]. Fourfold higher levels of cystatin C in the CSF than in blood [96] indicate a relevant role of the protein in CNS pathways. Cystatin C binds monomeric Abeta and carries soluble Abeta [97, 98]. There is evidence that AD patients have reduced CSF cystatin C levels [99, 100]. This makes it intriguing to hypothesize that a deficient Abeta-binding capacity, as induced by a lack of (functional) cystatin C, may contribute to the amyloidogenic process in AD [99]. Indeed, increased expression of this protein has been shown to reduce parenchymal Abeta load in mouse models of AD [101, 102]. Of note, the BB genotype of the cystatin C-encoding gene—which leads to reduced cystatin C secretion from the neuron to the extracellular space [103, 104]—conveys susceptibility to AD [105].
Inflammatory reactions, characterized by activated microglia and astrocytes surrounding amyloid deposits, are intimately associated with the onset and progress of AD [106–108]. Reactive astrocytes with Abeta-positive granules are found in close proximity to amyloid plaques. Human astrocytes express scavenger receptors and several Abeta-degrading enzymes such as NEP, insulin-degrading enzyme (IDE), endothelin-converting enzyme (ECE), angiotensin-converting enzyme (ACE), plasminogen activators, and the matrix metalloproteinases-9 and -2 (MMP-9, MMP-2) [109–112]. These findings suggest an important role of astrocytes in Abeta clearance.
Clinicopathological studies suggest that microglial activation is an early event in AD pathology [113, 114]. Activated microglia surround amyloid fibril deposits, and postmortem studies have shown significant amounts of Abeta in microglial cells of AD patients treated with immunization therapy [115, 116]. Microglia express toll-like receptors (TLRs), a family of highly conserved molecules that recognize pathogen-associated molecular patterns, including both exogenous and endogenous ligands [117]. TLR2 and TLR4 have been associated with the removal of Abeta, indicating that the innate immune system plays a key role in preventing the brain from Abeta deposits [118–120].
In addition, the adaptive immune system is obviously involved in CNS parenchyma clearance mechanisms. Naturally occurring antibodies directed against Abeta have been detected in the CSF and plasma of patients with AD and healthy control subjects. Some studies have shown reduced CSF levels of anti-Abeta antibodies in patients with AD compared with healthy control subjects [32, 121] and in individuals at increased risk for AD [122]. Another study reported that a subset of conformation-specific, cross-reactive antibodies that may protect against amyloidogenic toxic peptides are reduced in AD patients [123]. As a consequence of these findings, a number of phase II and III clinical trials are currently under way to test the effect of such autoantibodies in AD patients [124]. First results are promising: a recent study using carbon 11-labeled Pittsburgh Compound B ([11C]PiB) positron emission tomography (PET) has shown that passive immunization can reduce the level of brain amyloid in vivo after 18 months of antibody treatment [125].
5. Abeta Clearance in Lewy Body Disorders5.1. Intraneuronal Mechanisms
To the best of our knowledge there is no study available that investigated intraneuronal mechanisms of Abeta clearance in LBDs. There is however indirect evidence that deficits of (intraneuronal) defence mechanisms against Abeta toxicity may exist, at least in demented LBDs patients. We recently showed that CSF levels of uric acid, an antioxidant detectable in neurons and associated with PD progression, were significantly lower in demented than in nondemented LBDs patients. In addition, these levels correlated positively with CSF Abeta42 levels, with highest correlation values in controls and lowest in demented LBDs patients [126]. In the light of the recent finding that CSF Abeta levels increase within hours after trauma and thus reflect a sufficient and fast response to neuronal stress [127], a weak correlation of CSF Abeta42 with uric acid may indicate deficits in this repair mechanism.
5.2. Extraneuronal Mechanisms (Mainly)
Lowered CSF NEP activity levels have been found in demented LBDs patients, compared to nondemented LBDs patients and controls [128]. In addition, CSF NEP activity levels correlated positively with CSF Abeta42. These data argue for a role of NEP in the pathophysiology of cognitive decline in LBDs.
Also cystatin C seems to be relevantly involved in Abeta-associated cognitive decline in LBDs. Our group investigated CSF and serum levels in LBDs patients [129] and found lower CSF cystatin C levels in demented LBDs patients compared to PDND and controls. In additions, these levels correlated positively with age at onset of dementia but not with parameters associated with Parkinsonism. Notably, the correlation between CSF cystatin C and CSF Abeta42 levels was highly significant in nondemented individuals, but not significant in demented patients. This indicates that cystatin C-related Abeta transport from the neuron to the CSF is impaired in demented LBDs patients. This hypothesis is corroborated by genetic results [129]. The risk genotype of the CST3 gene, BB, was detectable only in demented LBDs patients and was associated with low CSF cystatin C levels.
The role of the innate immune system in Abeta clearance in LBDs is not well understood although neuroinflammatory reactions are a common finding in LBDs and are considered to play a key role in the neurodegenerative process [63]. There is a tight association of microglia with degenerating LB-containing neurons [130]. Activated microglia is associated with Asyn-positive oligodendrocytes in MSA patients and in an animal model of this disease [131, 132]. Astrocytic abnormalities also occur [133, 134].
The adaptive immune system is also involved in Abeta-associated mechanisms in LBDs. Autoantibodies against Abeta were elevated in serum and CSF of demented LBDs patients, compared to controls and were even higher than in other forms of dementia such vascular dementia [72]. Still, many questions remain about the contribution of the immune system, such as microglia, macrophages, and T cells but also other immune cells, to clearance of misfolded proteins in the CNS.
6. Conclusion
Although many questions remain open, recent literature suggests that impairment of protein clearance is one of the key factors mediating the degeneration of vulnerable neuronal populations in LBDs. Both intra- and extraneuronal clearance mechanisms are impaired in LBDs. An improved understanding of such pathways can provide the basis for new developments in the biomarker era and, ultimately, contribute to the development of neuromodulatory or even causal treatment strategies.
KahleP. J.α-Synucleinopathy models and human neuropathology: similarities and differences2008115187952-s2.0-3694903126710.1007/s00401-007-0302-xGasserT.Molecular pathogenesis of Parkinson disease: insights from genetic studies200911, article e222-s2.0-6914908903610.1017/S1462399409001148ScholzS. W.HouldenH.SchulteC.SharmaM.LiA.BergD.MelchersA.PaudelR.GibbsJ. R.Simon-SanchezJ.Paisan-RuizC.BrasJ.DingJ.ChenH.TraynorB. J.ArepalliS.ZonoziR. R.ReveszT.HoltonJ.WoodN.LeesA.OertelW.WüllnerU.GoldwurmS.PellecchiaM. T.IlligT.RiessO.FernandezH. H.RodriguezR. L.OkunM. S.PoeweW.WenningG. K.HardyJ. A.SingletonA. B.GasserT.SNCA variants are associated with increased risk for multiple system atrophy20096556106142-s2.0-6724913965510.1002/ana.21685LippaC. F.DudaJ. E.GrossmanM.HurtigH. I.AarslandD.BoeveB. F.BrooksD. J.DicksonD. W.DuboisB.EmreM.FahnS.FarmerJ. M.GalaskoD.GalvinJ. E.GoetzC. G.GrowdonJ. H.Gwinn-HardyK. A.HardyJ.HeutinkP.IwatsuboT.KosakaK.LeeV. M. Y.LeverenzJ. B.MasliahE.McKeithI. G.NussbaumR. L.OlanowC. W.RavinaB. M.SingletonA. B.TannerC. M.TrojanowskiJ. Q.WszolekZ. K.DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers200768118128192-s2.0-3404722323210.1212/01.wnl.0000256715.13907.d3BabaM.NakajoS.TuP. H.TomitaT.NakayaK.LeeV. M. Y.TrojanowskiJ. Q.IwatsuboT.Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies199815248798842-s2.0-0031941058GelbD. J.OliverE.GilmanS.Diagnostic criteria for Parkinson disease199956133392-s2.0-003293705910.1001/archneur.56.1.33EmreM.AarslandD.BrownR.BurnD. J.DuyckaertsC.MizunoY.BroeG. A.CummingsJ.DicksonD. W.GauthierS.GoldmanJ.GoetzC.KorczynA.LeesA.LevyR.LitvanI.McKeithI.OlanowW.PoeweW.QuinnN.SampaioC.TolosaE.DuboisB.Clinical diagnostic criteria for dementia associated with Parkinson's disease20072212168917072-s2.0-3534893960310.1002/mds.21507McKeithI. G.DicksonD. W.LoweJ.EmreM.O'BrienJ. T.FeldmanH.CummingsJ.DudaJ. E.LippaC.PerryE. K.AarslandD.AraiH.BallardC. G.BoeveB.BurnD. J.CostaD.Del SerT.DuboisB.GalaskoD.GauthierS.GoetzC. G.Gomez-TortosaE.HallidayG.HansenL. A.HardyJ.IwatsuboT.KalariaR. N.KauferD.KennyR. A.KorczynA.KosakaK.LeeV. M. Y.LeesA.LitvanI.LondosE.LopezO. L.MinoshimaS.MizunoY.MolinaJ. A.Mukaetova-LadinskaE. B.PasquierF.PerryR. H.SchulzJ. B.TrojanowskiJ. Q.YamadaM.Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium20056512186318722-s2.0-3374565940710.1212/01.wnl.0000187889.17253.b1JellingerK. A.SeppiK.WenningG. K.Clinical and neuropathological correlates of Lewy body disease (multiple letters)200310621881892-s2.0-003759239510.1007/s00401-003-0721-2BollerF.MizutaniT.RoessmannU.GambettiP.Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations1980743293352-s2.0-0018897531BraakH.RübU.Jansen SteurE. N. H.Del TrediciK.de VosR. A. I.Cognitive status correlates with neuropathologic stage in Parkinson disease2005648140414102-s2.0-17644426053HughesA. J.DanielS. E.BlanksonS.LeesA. J.A clinicopathologic study of 100 cases of Parkinson's disease19935021401482-s2.0-0027465936MaetzlerW.LiepeltI.BergD.Progression of Parkinson's disease in the clinical phase: potential markers2009812115811712-s2.0-7184910469010.1016/S1474-4422(09)70291-1BallardC.ZiabrevaI.PerryR.LarsenJ. P.O'BrienJ.McKeithI.PerryE.AarslandD.Differences in neuropathologic characteristics across the Lewy body dementia spectrum20066711193119342-s2.0-3384570989910.1212/01.wnl.0000249130.63615.ccBrooksD. J.Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography200924supplement 2S742S7472-s2.0-7284910934310.1002/mds.22581MaetzlerW.LiepeltI.ReimoldM.ReischlG.SolbachC.BeckerC.SchulteC.LeyheT.KellerS.MelmsA.GasserT.BergD.Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics20093411071122-s2.0-6214914095410.1016/j.nbd.2008.12.008GerlachM.MaetzlerW.BroichK.HampelH.RemsL.ReumT.RiedererP.StöfflerA.StrefferJ.BergD.Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics2012119139522-s2.0-7996018383210.1007/s00702-011-0682-xHershkoA.CiechanoverA.The ubiquitin system1998674254792-s2.0-003165780710.1146/annurev.biochem.67.1.425SchwartzA. L.CiechanoverA.The ubiquitin-proteasome pathway and pathogenesis of human diseases19995057742-s2.0-003301629110.1146/annurev.med.50.1.57CiechanoverA.BrundinP.The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg20034024274462-s2.0-014198786010.1016/S0896-6273(03)00606-8CuervoA. M.Autophagy: in sickness and in health200414270772-s2.0-044232356110.1016/j.tcb.2003.12.002KlionskyD. J.Autophagy2005158R282R2832-s2.0-23344446037MizushimaN.Autophagy: process and function20072122286128732-s2.0-3624902572310.1101/gad.1599207Martinez-VicenteM.CuervoA. M.Autophagy and neurodegeneration: when the cleaning crew goes on strike2007643523612-s2.0-3384765290010.1016/S1474-4422(07)70076-5DewittD. A.PerryG.CohenM.DollerC.SilverJ.Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease199814923293402-s2.0-1814445379610.1006/exnr.1997.6738LeeC. Y. D.LandrethG. E.The role of microglia in amyloid clearance from the AD brain201011789499602-s2.0-7795695575810.1007/s00702-010-0433-4TakumaK.FangF.ZhangW.YanS.FukuzakiE.DuH.SosunovA.McKhannG.FunatsuY.NakamichiN.NagaiT.MizoguchiH.IbiD.HoriO.OgawaS.SternD. M.YamadaK.YanS. S.RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction20091064720021200262-s2.0-7394908888310.1073/pnas.0905686106FuentealbaR. A.LiuQ.ZhangJ.KanekiyoT.HuX.LeeJ. M.LaduM. J.BuG.Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Aβ42 uptake and lysosomal trafficking2010572-s2.0-7795560455310.1371/journal.pone.0011884e11884KoprichJ. B.Reske-NielsenC.MithalP.IsacsonO.Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease20085, article 82-s2.0-4224911587710.1186/1742-2094-5-8DeleidiM.HallettP. J.KoprichJ. B.ChungC. Y.IsacsonO.The toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration2010304816091161012-s2.0-7864974583310.1523/JNEUROSCI.2400-10.2010PapachroniK. K.NinkinaN.PapapanagiotouA.HadjigeorgiouG. M.XiromerisiouG.PapadimitriouA.KalofoutisA.BuchmanV. L.Autoantibodies to α-synuclein in inherited Parkinson's disease200710137497562-s2.0-3424740208410.1111/j.1471-4159.2006.04365.xWekslerM. E.RelkinN.TurkenichR.LaRusseS.ZhouL.SzaboP.Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals20023779439482-s2.0-003608570210.1016/S0531-5565(02)00029-3BrettschneiderS.MorgenthalerN. G.TeipelS. J.Fischer-SchulzC.BürgerK.DodelR.DuY.MöllerH. J.BergmannA.HampelH.Decreased serum amyloid β1–42 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide20055778138162-s2.0-2014438725110.1016/j.biopsych.2004.12.008BraakH.Del TrediciK.RübU.de VosR. A. I.Jansen SteurE. N. H.BraakE.Staging of brain pathology related to sporadic Parkinson's disease20032421972112-s2.0-003733366610.1016/S0197-4580(02)00065-9HallettP. J.McLeanJ. R.KartunenA.LangstonJ. W.IsacsonO.α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits20124722582672-s2.0-8486170658110.1016/j.nbd.2012.04.009KaufmannH.NahmK.PurohitD.WolfeD.Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies2004636109310952-s2.0-4644323707WebbJ. L.RavikumarB.AtkinsJ.SkepperJ. N.RubinszteinD. C.α-Synuclein is degraded by both autophagy and the proteasome20032782725009250132-s2.0-004158924810.1074/jbc.M300227200CuervoA. M.StafanisL.FredenburgR.LansburyP. T.SulzerD.Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy20043055688129212952-s2.0-434465968510.1126/science.1101738TofarisG. K.LayfieldR.SpillantiniM. G.α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome2001509122262-s2.0-003597683510.1016/S0014-5793(01)03115-5SpencerB.PotkarR.TrejoM.RockensteinE.PatrickC.GindiR.AdameA.Wyss-CorayT.MasliahE.Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in α-synuclein models of Parkinson's and Lewy body diseases2009294313578135882-s2.0-7035055020810.1523/JNEUROSCI.4390-09.2009Martinez-VicenteM.TalloczyZ.KaushikS.MasseyA. C.MazzulliJ.MosharovE. V.HodaraR.FredenburgR.WuD. C.FollenziA.DauerW.PrzedborskiS.IschiropoulosH.LansburyP. T.SulzerD.CuervoA. M.Dopamine-modified α-synuclein blocks chaperone-mediated autophagy200811827777782-s2.0-3884917497910.1172/JCI32806StefanisL.LarsenK. E.RideoutH. J.SulzerD.GreeneL. A.Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death20012124954995602-s2.0-0035894855TanakaY.EngelenderS.IgarashiS.RaoR. K.WannerT.TanziR. E.SawaA.DawsonV. L.DawsonT. M.RossC. A.Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis20011099199262-s2.0-0035870881PetrucelliL.O'FarrellC.LockhartP. J.BaptistaM.KehoeK.VinkL.ChoiP.WolozinB.FarrerM.HardyJ.CooksonM. R.Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons2002366100710192-s2.0-003713770210.1016/S0896-6273(02)01125-XSnyderH.MensahK.TheislerC.LeeJ.MatouschekA.WolozinB.Aggregated and monomeric α-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function20032781411753117592-s2.0-003841375910.1074/jbc.M208641200Alvarez-ErvitiL.Rodriguez-OrozM. C.CooperJ. M.CaballeroC.FerrerI.ObesoJ. A.SchapiraA. H. V.Chaperone-mediated autophagy markers in Parkinson disease brains20106712146414722-s2.0-7814946972810.1001/archneurol.2010.198Vives-BauzaC.PrzedborskiS.Mitophagy: the latest problem for Parkinson's disease20111731581652-s2.0-7995245142710.1016/j.molmed.2010.11.002GeislerS.HolmströmK. M.SkujatD.FieselF. C.RothfussO. C.KahleP. J.SpringerW.PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM120101221191312-s2.0-7594913082810.1038/ncb2012MichiorriS.GelmettiV.GiardaE.LombardiF.RomanoF.MarongiuR.Nerini-MolteniS.SaleP.VagoR.ArenaG.TorosantucciL.CassinaL.RussoM. A.DallapiccolaB.ValenteE. M.CasariG.The Parkinson-associated protein PINK1 interacts with Beclin1 and promotes autophagy20101769629742-s2.0-7795224257210.1038/cdd.2009.200McCoyM. K.CooksonM. R.DJ-1 regulation of mitochondrial function and autophagy through oxidative stress2011755315322-s2.0-7995570161110.4161/auto.7.5.14684TongY.YamaguchiH.GiaimeE.BoyleS.KopanR.KelleherR. J.ShenJ.Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice201010721987998842-s2.0-7795309047810.1073/pnas.1004676107Gómez-SuagaP.Luzón-ToroB.ChuramaniD.ZhangL.Bloor-YoungD.PatelS.WoodmanP. G.ChurchillG. C.HilfikerS.Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP20122135115252-s2.0-8486290794310.1093/hmg/ddr481MazzulliJ. R.XuY. H.SunY.KnightA. L.McLeanP. J.CaldwellG. A.SidranskyE.GrabowskiG. A.KraincD.Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies2011146137522-s2.0-7996000980410.1016/j.cell.2011.06.001SchmidS. P.SchleicherE. D.CeganA.DeuschleC.BaurS.HauserA.-K.SynofzikM.SrulijesK.BrockmannK.BergD.MaetzlerW.Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease20122722882932-s2.0-8485697550410.1002/mds.23984LeeH. J.PatelS.LeeS. J.Intravesicular localization and exocytosis of α-synuclein and its aggregates20052525601660242-s2.0-2134445650610.1523/JNEUROSCI.0692-05.2005El-AgnafO. M.SalemS. A.PaleologouK. E.CooperL. J.FullwoodN. J.α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma2003171319451947MollenhauerB.LocascioJ. J.Schulz-SchaefferW.Sixel-DöringF.TrenkwalderC.SchlossmacherM. G.α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study20111032302402-s2.0-7995172085610.1016/S1474-4422(11)70014-XCicchettiF.BrownellA. L.WilliamsK.ChenY. I.LivniE.IsacsonO.Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging20021569919982-s2.0-003645933510.1046/j.1460-9568.2002.01938.xSánchez-PernauteR.FerreeA.CooperO.YuM.BrownellA. L.IsacsonO.Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease20041, article 62-s2.0-434464571910.1186/1742-2094-1-6DeleidiM.IsacsonO.Viral and inflammatory triggers of neurodegenerative diseases20124121121ps32-s2.0-8485722554310.1126/scitranslmed.3003492TeismannP.SatheK.BierhausA.LengL.MartinH. L.BucalaR.WeigleB.NawrothP. P.SchulzJ. B.Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity20123310247824902-s2.0-8486437921410.1016/j.neurobiolaging.2011.12.006MaetzlerW.BergD.SchalamberidzeN.MelmsA.SchottK.MuellerJ. C.LiawL.GasserT.NitschC.Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model20072534734822-s2.0-3384723766710.1016/j.nbd.2006.10.020HallidayG. M.StevensC. H.Glia: initiators and progressors of pathology in Parkinson's disease20112616172-s2.0-7995149917610.1002/mds.23455GuX. L.LongC. X.SunL.XieC.LinX.CaiH.Astrocytic expression of Parkinson's disease-related A53T α-synuclein causes neurodegeneration in mice201031, article 122-s2.0-7795107731710.1186/1756-6606-3-12MackenzieI. R. A.Activated microglia in dementia with Lewy bodies20005511321342-s2.0-0034641287BraakH.SastreM.Del TrediciK.Development of α-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease200711432312412-s2.0-3454772731210.1007/s00401-007-0244-3LeeH. J.SukJ. E.BaeE. J.LeeS. J.Clearance and deposition of extracellular α-synuclein aggregates in microglia200837234234282-s2.0-4474909014710.1016/j.bbrc.2008.05.045HamzaT. H.ZabetianC. P.TenesaA.LaederachA.MontimurroJ.YearoutD.KayD. M.DohenyK. F.PaschallJ.PughE.KuselV. I.ColluraR.RobertsJ.GriffithA.SamiiA.ScottW. K.NuttJ.FactorS. A.PayamiH.Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease20104297817852-s2.0-7795664616710.1038/ng.642SaikiM.BakerA.Williams-GrayC. H.FoltynieT.GoodmanR. S.TaylorC. J.CompstonD. A. S.BarkerR. A.SawcerS. J.GorisA.Association of the human leucocyte antigen region with susceptibility to Parkinson's disease20108188908912-s2.0-7795575902010.1136/jnnp.2008.162883KreutzbergG. W.Microglia: a sensor for pathological events in the CNS19961983123182-s2.0-003022203710.1016/0166-2236(96)10049-7OrrC. F.RoweD. B.MizunoY.MoriH.HallidayG. M.A possible role for humoral immunity in the pathogenesis of Parkinson's disease200512811266526742-s2.0-2764453185710.1093/brain/awh625MaetzlerW.BergD.SynofzikM.BrockmannK.GodauJ.MelmsA.GasserT.HörnigS.LangkampM.Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of lewy body-associated dementias20112611711792-s2.0-8005285084310.3233/JAD-2011-110221HongZ.ShiM.ChungK. A.QuinnJ. F.PeskindE. R.GalaskoD.JankovicJ.ZabetianC. P.LeverenzJ. B.BairdG.MontineT. J.HancockA. M.HwangH.PanC.BradnerJ.KangU. J.JensenP. H.ZhangJ.DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease201013337137262-s2.0-7795022368710.1093/brain/awq008ShiM.BradnerJ.HancockA. M.ChungK. A.QuinnJ. F.PeskindE. R.GalaskoD.JankovicJ.ZabetianC. P.KimH. M.LeverenzJ. B.MontineT. J.GinghinaC.KangU. J.CainK. C.WangY.AaslyJ.GoldsteinD.ZhangJ.Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression20116935705802-s2.0-7995328386810.1002/ana.22311MollenhauerB.CullenV.KahnI.KrastinsB.OuteiroT. F.PepivaniI.NgJ.Schulz-SchaefferW.KretzschmarH. A.McLeanP. J.TrenkwalderC.SarracinoD. A.VonSattelJ. P.LocascioJ. J.El-AgnafO. M. A.SchlossmacherM. G.Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration200821323153252-s2.0-4944910599010.1016/j.expneurol.2008.06.004TokudaT.SalemS. A.AllsopD.MizunoT.NakagawaM.QureshiM. M.LocascioJ. J.SchlossmacherM. G.El-AgnafO. M. A.Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease200634911621662-s2.0-3374832584810.1016/j.bbrc.2006.08.024TokudaT.QureshiM. M.ArdahM. T.VargheseS.ShehabS. A. S.KasaiT.IshigamiN.TamaokaA.NakagawaM.El-AgnafO. M. A.Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease20107520176617722-s2.0-7864999007910.1212/WNL.0b013e3181fd613bWangY.ShiM.ChungK. A.ZabetianC. P.LeverenzJ. B.BergD.SrulijesK.TrojanowskiJ. Q.LeeV. M. Y.SiderowfA. D.HurtigH.LitvanI.SchiessM. C.PeskindE. R.MasudaM.HasegawaM.LinX.PanC.GalaskoD.GoldsteinD. S.JensenP. H.YangH.CainK. C.ZhangJ.Phosphorylated α-synuclein in Parkinson's disease20124121ra1202-s2.0-8486316499410.1126/scitranslmed.3002566ScheunerD.EckmanC.JensenM.SongX.CitronM.SuzukiN.BirdT. D.HardyJ.HuttonM.KukullW.LarsonE.Levy-LahadE.ViitanenM.PeskindE.PoorkajP.SchellenbergG.TanziR.WascoW.LannfeltL.SelkoeD.YounkinS.Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease1996288648702-s2.0-1604437352410.1038/nm0896-864MawuenyegaK. G.SigurdsonW.OvodV.MunsellL.KastenT.MorrisJ. C.YarasheskiK. E.BatemanR. J.Decreased clearance of CNS β-amyloid in Alzheimer's disease20103306012, article 17742-s2.0-7865067868810.1126/science.1197623NixonR. A.WegielJ.KumarA.YuW. H.PeterhoffC.CataldoA.CuervoA. M.Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study20056421131222-s2.0-14844303381YuW. H.CuervoA. M.KumarA.PeterhoffC. M.SchmidtS. D.LeeJ. H.MohanP. S.MerckenM.FarmeryM. R.TjernbergL. O.JiangY.DuffK.UchiyamaY.NäslundJ.MathewsP. M.CataldoA. M.NixonR. A.Macroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease2005171187982-s2.0-2644458750810.1083/jcb.200505082NixonR. A.Autophagy, amyloidogenesis and Alzheimer disease200712023408140912-s2.0-3834904697310.1242/jcs.019265BolandB.KumarA.LeeS.PlattF. M.WegielJ.YuW. H.NixonR. A.Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease20082827692669372-s2.0-4904909656210.1523/JNEUROSCI.0800-08.2008PickfordF.MasliahE.BritschgiM.LucinK.NarasimhanR.JaegerP. A.SmallS.SpencerB.RockensteinE.LevineB.Wyss-CorayT.The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid β accumulation in mice20081186219021992-s2.0-4574911489510.1172/JCI33585LeeJ. H.YuW. H.KumarA.LeeS.MohanP. S.PeterhoffC. M.WolfeD. M.Martinez-VicenteM.MasseyA. C.SovakG.UchiyamaY.WestawayD.CuervoA. M.NixonR. A.Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations20101417114611582-s2.0-7795391305110.1016/j.cell.2010.05.008WellerR. O.YowH. Y.PrestonS. D.MazantiI.NicollJ. A. R.Cerebrovascular disease is a major factor in the failure of elimination of Aβ from the aging human brain: implications for therapy of Alzheimer's disease20029771621682-s2.0-0036450037NalivaevaN. N.FiskL. R.BelyaevN. D.TurnerA. J.Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease2008522122242-s2.0-4214912551010.2174/156720508783954785HawkesC. A.HärtigW.KaczaJ.SchliebsR.WellerR. O.NicollJ. A.CarareR. O.Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy201112144314432-s2.0-7995462328210.1007/s00401-011-0801-7HowellS.NalbantogluJ.CrineP.Neutral endopeptidase can hydrolyze β-amyloid(1–40) but shows no effect on β-amyloid precursor protein metabolism19951646476522-s2.0-002906168510.1016/0196-9781(95)00021-BIwataN.TsubukiS.TakakiY.ShirotaniK.LuB.GerardN. P.GerardC.HamaE.LeeH. J.SaidoT. C.Metabolic regulation of brain Aβ by neprilysin20012925521155015522-s2.0-003594720710.1126/science.1059946SpillantiniM. G.SicuteriF.SalmonS.MalfroyB.Characterization of endopeptidase 3.4.24.11 (“enkephalinase”) activity in human plasma and cerebrospinal fluid1990398135313562-s2.0-002527786210.1016/0006-2952(90)90012-ANalivaevaN. N.FiskL.KochkinaE. G.PlesnevaS. A.ZhuravinI. A.BabusikovaE.DobrotaD.TurnerA. J.Effect of hypoxia/ischemia and hypoxic preconditioning/reperfusion on expression of some amyloid-degrading enzymes2004103521332-s2.0-1494438097810.1196/annals.1332.002IwataN.TakakiY.FukamiS.TsubukiS.SaidoT. C.Region-specific reduction of Aβ-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging20027034935002-s2.0-003701028610.1002/jnr.10390NishioC.YoshidaK.NishiyamaK.HatanakaH.YamadaM.Involvement of cystatin C in oxidative stress-induced apoptosis of cultured rat CNS neurons200087322522622-s2.0-003463729610.1016/S0006-8993(00)02540-3GrubbA.Diagnostic value of analysis of cystatin C and protein HC in biological fluids199238supplement 1S20S272-s2.0-0027058414SelenicaM. L.WangX.Ostergaard-PedersenL.Westlind-DanielssonA.GrubbA.Cystatin C reduces the in vitro formation of soluble Aβ1–42 oligomers and protofibrils20076721791902-s2.0-3394713367110.1080/00365510601009738SastreM.CaleroM.PawlikM.MathewsP. M.KumarA.DanilovV.SchmidtS. D.NixonR. A.FrangioneB.LevyE.Binding of cystatin C to Alzheimer's amyloid β inhibits in vitro amyloid fibril formation2004258103310432-s2.0-294273705110.1016/j.neurobiolaging.2003.11.006HanssonS. F.AndréassonU.WallM.SkoogI.AndreasenN.WallinA.ZetterbergH.BlennowK.Reduced levels of amyloid-β-binding proteins in cerebrospinal fluid from Alzheimer's disease patients20091623893972-s2.0-6034910141110.3233/JAD-2009-0966SimonsenA. H.McGuireJ.PodustV. N.HagneliusN. O.NilssonT. K.KapakiE.VassilopoulosD.WaldemarG.A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia20072464344402-s2.0-3644899779810.1159/000110576KaeserS. A.HerzigM. C.CoomaraswamyJ.KilgerE.SelenicaM. L.WinklerD. T.StaufenbielM.LevyE.GrubbA.JuckerM.Cystatin C modulates cerebral β-amyloidosis20073912143714392-s2.0-3654908508610.1038/ng.2007.23MiW.PawlikM.SastreM.JungS. S.RadvinskyD. S.KleinA. M.SommerJ.SchmidtS. D.NixonR. A.MathewsP. M.LevyE.Cystatin C inhibits amyloid-β deposition in Alzheimer's disease mouse models20073912144014422-s2.0-3654904390010.1038/ng.2007.29BenussiL.GhidoniR.SteinhoffT.AlbericiA.VillaA.MazzoliF.NicosiaF.BarbieroL.BroglioL.FeudatariE.SignoriniS.FinckhU.NitschR. M.BinettiG.Alzheimer disease-associated cystatin C variant undergoes impaired secretion200313115212-s2.0-003839975710.1016/S0969-9961(03)00012-3ParaoanL.RatnayakaA.SpillerD. G.HiscottP.WhiteM. R. H.GriersonI.Unexpected intracellular localization of the AMD-associated cystatin C variant20045118848952-s2.0-724422153710.1111/j.1600-0854.2004.00230.xDehghanA.KöttgenA.YangQ.HwangS. J.KaoW. L.RivadeneiraF.BoerwinkleE.LevyD.HofmanA.AstorB. C.BenjaminE. J.van DuijnC. M.WittemanJ. C.CoreshJ.FoxC. S.Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study20083729654195319612-s2.0-5704908398110.1016/S0140-6736(08)61343-4McGeerE. G.McGeerP. L.Brain inflammation in Alzheimer disease and the therapeutic implications19995108218362-s2.0-0032731763AkiyamaH.BargerS.BarnumS.BradtB.BauerJ.ColeG. M.CooperN. R.EikelenboomP.EmmerlingM.FiebichB. L.FinchC. E.FrautschyS.GriffinW. S. T.HampelH.HullM.LandrethG.LueL. F.MrakR.MacKenzieI. R.McGeerP. L.O'BanionM. K.PachterJ.PasinettiG.Plata-SalamanC.RogersJ.RydelR.ShenY.StreitW.StrohmeyerR.TooyomaI.van MuiswinkelF. L.VeerhuisR.WalkerD.WebsterS.WegrzyniakB.WenkG.Wyss-CorayT.Inflammation and Alzheimer's disease20002133834212-s2.0-003461217510.1016/S0197-4580(00)00124-XAlexanderJ. J.AndersonA. J.BarnumS. R.StevensB.TennerA. J.The complement cascade: Yin-Yang in neuroinflammation—neuro-protection and -degeneration20081075116911872-s2.0-5584911495510.1111/j.1471-4159.2008.05668.xHusemannJ.SilversteinS. C.Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain200115838258322-s2.0-0035101055AllamanI.GavilletM.BélangerM.LarocheT.ViertlD.LashuelH. A.MagistrettiP. J.Amyloid-β aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability2010309332633382-s2.0-7774933662710.1523/JNEUROSCI.5098-09.2010LeissringM. A.The AβCs of Aβ-cleaving proteases20082834429645296492-s2.0-5764917832210.1074/jbc.R800022200TurnerA. J.NalivaevaN. N.New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection2007821131352-s2.0-3454732807410.1016/S0074-7742(07)82006-XHoozemansJ. J. M.van HaastertE. S.VeerhuisR.ArendtT.ScheperW.EikelenboomP.RozemullerA. J. M.Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease20052, article 272-s2.0-2834443969910.1186/1742-2094-2-27CagninA.BrooksD. J.KennedyA. M.GunnR. N.MyersR.TurkheimerF. E.JonesT.BanatiR. B.In-vivo measurement of activated microglia in dementia200135892804614672-s2.0-003584528310.1016/S0140-6736(01)05625-2ItagakiS.McGeerP. L.AkiyamaH.ZhuS.SelkoeD.Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease19892431731822-s2.0-0024436506NicollJ. A.BartonE.BocheD.NealJ. W.FerrerI.Aβ species removal after Aβ42 immunization200665111040104810.1097/01.jnen.0000240466.10758.ceGlezerI.SimardA. R.RivestS.Neuroprotective role of the innate immune system by microglia200714748678832-s2.0-3454712763210.1016/j.neuroscience.2007.02.055LiuY.WalterS.StagiM.ChernyD.LetiembreM.Schulz-SchaefferW.HeineH.PenkeB.NeumannH.FassbenderK.LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide20051288177817892-s2.0-2344444827710.1093/brain/awh531TaharaK.KimH. D.JinJ. J.MaxwellJ. A.LiL.FukuchiK. I.Role of toll-like receptor signalling in Aβ uptake and clearance200612911300630192-s2.0-3375057699310.1093/brain/awl249RichardK. L.FilaliM.PréfontaineP.RivestS.Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid β1–42 and delay the cognitive decline in a mouse model of Alzheimer's disease20082822578457932-s2.0-4594910607710.1523/JNEUROSCI.1146-08.2008DuY.DodelR.HampelH.BuergerK.LinS.EastwoodB.BalesK.GaoF.MoellerH. J.OertelW.FarlowM.PaulS.Reduced levels of amyloid β-peptide antibody in Alzheimer disease20015758018052-s2.0-0035845614MaetzlerW.LangkampM.LercheS.GodauJ.BrockmannK.Lowered serum amyloid-beta1–42 autoantibodies in individuals with lifetime depression20123219510010.3233/JAD-2012-120625BritschgiM.OlinC. E.JohnsH. T.Takeda-UchimuraY.LemieuxM. C.RufibachK.RajadasJ.ZhangH.TomookaB.RobinsonW. H.ClarkC. M.FaganA. M.GalaskoD. R.HoltzmanD. M.JutelM.KayeJ. A.LemereC. A.LeszekJ.LiG.PeskindE. R.QuinnJ. F.YesavageJ. A.GhisoJ. A.Wyss-CorayT.Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease20091062912145121502-s2.0-6774912258110.1073/pnas.0904866106HampelH.PrvulovicD.TeipelS.JessenF.LuckhausC.FrölichL.RiepeM. W.DodelR.LeyheT.BertramL.HoffmannW.FaltracoF.The future of Alzheimer's disease: the next 10 years20119547187282-s2.0-8275516199210.1016/j.pneurobio.2011.11.008RinneJ. O.BrooksD. J.RossorM. N.FoxN. C.BullockR.KlunkW. E.MathisC. A.BlennowK.BarakosJ.OkelloA. A.de LIanoS. R. M.LiuE.KollerM.GreggK. M.SchenkD.BlackR.GrundmanM.11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study2010943633722-s2.0-7794930079610.1016/S1474-4422(10)70043-0MaetzlerW.StapfA. K.SchulteC.HauserA.-K.LercheS.WursterI.SchleicherE.MelmsA.BergD.Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-β pathway20112711191262-s2.0-8015519007910.3233/JAD-2011-110587BrodyD. L.MagnoniS.SchwetyeK. E.SpinnerM. L.EsparzaT. J.StocchettiN.ZipfelG. J.HoltzmanD. M.Amyloid-β dynamics correlate with neurological status in the injured human brain20083215893122112242-s2.0-5064911461110.1126/science.1161591MaetzlerW.StoychevaV.SchmidB.SchulteC.HauserA. K.BrockmannK.MelmsA.GasserT.BergD.Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in lewy body disease20102239339382-s2.0-7865065608810.3233/JAD-2010-101197MaetzlerW.SchmidB.SynofzikM.SchulteC.RiesterK.HuberH.BrockmannK.GasserT.BergD.MelmsA.The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in lewy body disease20101939379422-s2.0-7714916542410.3233/JAD-2010-1289IsekiE.MaruiW.AkiyamaH.UédaK.KosakaK.Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using α-synuclein-immunohistochemistry2000286169732-s2.0-003471725610.1016/S0304-3940(00)01090-9IshizawaK.KomoriT.SasakiS.AraiN.MizutaniT.HiroseT.Microglial activation parallels system degeneration in multiple system atrophy200463143522-s2.0-0347419472StefanovaN.ReindlM.NeumannM.HaassC.PoeweW.KahleP. J.WenningG. K.Oxidative stress in transgenic mice with oligodendroglial α-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy200516638698762-s2.0-14644417871HishikawaN.HashizumeY.YoshidaM.NiwaJ. I.TanakaF.SobueG.Tuft-shaped astrocytes in Lewy body disease200510943733802-s2.0-1834436543310.1007/s00401-004-0967-3TeradaS.IshizuH.YokotaO.TsuchiyaK.NakashimaH.IshiharaT.FujitaD.UédaK.IkedaK.KurodaS.Glial involvement in diffuse Lewy body disease200310521631692-s2.0-0037313281